Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Vivos Therapeutics (VVOS) Operating Margin (2020 - 2025)

Vivos Therapeutics has reported Operating Margin over the past 6 years, most recently at 166.89% for Q4 2025.

  • Quarterly Operating Margin fell 9101.0% to 166.89% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 114.08% through Dec 2025, down 3975.0% year-over-year, with the annual reading at 114.05% for FY2025, 3973.0% down from the prior year.
  • Operating Margin was 166.89% for Q4 2025 at Vivos Therapeutics, down from 69.79% in the prior quarter.
  • Over five years, Operating Margin peaked at 198.22% in Q4 2021 and troughed at 182.19% in Q1 2022.
  • The 5-year median for Operating Margin is 124.15% (2021), against an average of 101.93%.
  • Year-over-year, Operating Margin skyrocketed 38717bps in 2021 and then tumbled -35172bps in 2022.
  • A 5-year view of Operating Margin shows it stood at 198.22% in 2021, then plummeted by -177bps to 153.49% in 2022, then grew by 17bps to 127.25% in 2023, then skyrocketed by 40bps to 75.88% in 2024, then tumbled by -120bps to 166.89% in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Operating Margin are 166.89% (Q4 2025), 69.79% (Q3 2025), and 127.36% (Q2 2025).